Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H (HK:6990) has released an update.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has received approval from China’s National Medical Products Administration for a clinical trial of its innovative drug SKB501, designed to treat advanced solid tumors. This novel ADC drug, developed using the company’s OptiDC platform, has shown promising results in preclinical studies. Investors are advised to exercise caution as there is no guarantee of successful commercialization.
For further insights into HK:6990 stock, check out TipRanks’ Stock Analysis page.